NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- The global hemophilia treatment market was estimated at USD 11.65 billion in 2017 and is expected to reach USD 15.85 billion in 2024 at a CAGR of 4.02% during the forecast period. Hemophilia is a genetic disease that results in deficiency of proteins that leads to blood clotting.
Novel Drug Development is Creating A Wave of Change in the Market
On the basis of hemophilia types, the market have been segmented into type A & B. Hemophilia A & B is caused by deficiency or dysfunctional of coagulation factor VIII and factor IX respectively. The deficiency or absence of one of these factors may disrupt the blood clotting factor. People with bleeding disorders experience extended bleeding after trauma, injury, menstruation, and surgery. Many major players focus on novel drug development in the treatment of hemophilia. Recently European Commission has approved Roche ‘’Hemlibra’’ for treatment of hemophilia A with factor VIII inhibitors. Japan’s Ministry of Health, Labor, and Welfare (MHLW) has approved CSL Behring’s “AFSTYLA” for the treatment of hemophilia A.
Major players are investing in research and development activities for the development of novel drugs that can treat both types of hemophilia. The treatment of hemophilia depends upon the type of hemophilia and the severity of hemophilia. Currently, medical scientists focus on the gene therapy; it is a novel approach to the treatment of hemophilia. Gene therapy is a novel approach to the treatment of hemophilia. In this treatment the gene transfer through IV infusion and giving an individual with hemophilia a function FVIII or FIX gene
Hemophilia Treatment Market Regional Insight
North America held major share of the global market in 2017. The growth in the region is attributed to growing number of people affected with hemophilia disease. Asia-Pacific region is expected to witness the fastest growth during the forecast period owing to growing number of drugs approval, and advancement in diagnostic technology.
Browse full research report with TOC on “Global Hemophilia Treatment Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024” at: https://www.energiasmarketresearch.com/global-hemophilia-treatment-market-report/
To purchase report: sales@energiasmarketresearch.com
Key findings from the report:
- On the basis of type, the hemophilia a segment held the major share of the market in 2017, due to growing number of patient’s diagnosis with Hemophilia Treatment A. Hemophilia B is expected to grow at rapid rate in the coming period. The increasing cases of people getting affected with Hemophilia B are the major factor.
- On the basis of distribution channel, the hospital segment held major share of the market share in 2017
- Geographically, North America held the largest share in the market in 2017 owing to rising prevalence of hemophilia disease and increasing awareness about the treatments and advanced products in the region. Asia pacific is expected to witness significant growth in the market.
- Some of the key companies operating in the market include Novo Nordisk A/S; Sanofi; Bayer AG; Pfizer Inc.; Grifols, S.A.; Octapharma AG; Kedrion S.p.A; Baxter International Inc.; CSL Behring; Swedish Orphan Biovitrum AB ; Shire plc; and F. Hoffmann-La Roche Ltd. These companies are involved in many awareness and treatment programs launched by their governments and various hemophilia associations and organizations.
This report segments global hemophilia treatment market by type, sex, product, therapy, distribution channel, and region
By Type
- Hemophilia A
- Hemophilia B
- Others
By Sex
- Male
- Female
By Product
- Recombinant Coagulation Factor Concentrates
- Plasma Derived Coagulation Factor Concentrates
- Desmopressin
- Antifibrinolytic Agents
By Therapy
- Factor Replacement Therapy
- Gene Therapy
- Immune Tolerance Induction therapy
By Distribution Channel
- Retail Pharmacies
- Hospitals
- E-commerce
By Region
- North America
- Latin America
- Europe
- Asia-Pacific
- Middle East and Africa
About Energias Market Research Pvt. Ltd. -
Energias Market Research Pvt. Ltd. publishes high quality reports, in-depth market research studies, to help clients obtain investment level clarity on current business scenario, trends and segmentation for their future developments. We are committed to our client’s needs, by providing high quality custom reports solutions best fit for strategy development and implementation to high return of invest (RoI). We believe that exceptional problems need expertise to solve, and with the help of our industries expertise we are able to offer an in depth understanding of what’s crucial, what’s applicable, and what it takes to ensure accomplishment in any business or venture.
With a wide range of expertise from various industrial sectors and more than 50 industries that includes energy, chemical and materials, information and communication technology, semiconductor and electronics industries, healthcare and daily consumer goods, etc. We strive to provide our clients with a one-stop solution for all research and consulting needs. Follow Energias Market Research on Twitter at @energiasmr.
Contact:
Mr. Manas Nagi
Business Development Manager
For any queries email us: info@energiasmarketresearch.com
To purchase report: sales@energiasmarketresearch.com
Call us: +1-716-239-4915